Research programme: ion trap technology based therapeutics - ZS Pharma

Drug Profile

Research programme: ion trap technology based therapeutics - ZS Pharma

Alternative Names: Non absorbed binders - ZS Pharma

Latest Information Update: 24 Dec 2015

Price : $50

At a glance

  • Originator ZS Pharma
  • Class Minerals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cardiovascular disorders; Kidney disorders; Liver disorders; Metabolic disorders

Most Recent Events

  • 17 Dec 2015 ZS Pharma has been acquired by AstraZeneca
  • 14 Aug 2014 Early research in Cardiovascular disorders in USA (unspecified route)
  • 14 Aug 2014 Early research in Kidney disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top